ALS tests positive for Life Sciences growth
ALS (ASX:ALQ) reported underlying revenue of $1.46bn for the half year ending 30 September 2024, up 14% year-on-year. Growth was driven by robust performance in the Life Sciences division, which saw revenue climb 25.6%, offsetting softer conditions in the Commodities division.
Read More